The $315 Pill That Could Change Everything: FDA Approves First Oral Drug That Slashes Cholesterol by 60%

 

The $315 Pill That Could Change Everything: FDA Approves First Oral Drug That Slashes Cholesterol by 60%

**For the first time in history, patients can get injectable-level cholesterol reduction from a once-a-day pill. The era of the needle may finally be over.**

---

## Introduction: The End of the Needle

For more than a decade, the most powerful cholesterol-lowering drugs have come with a catch: they required a needle. Injectable PCSK9 inhibitors like Amgen's Repatha and Regeneron's Praluent have been available since 2015, offering dramatic reductions in "bad" LDL cholesterol. But they've never achieved widespread adoption. The reasons are familiar: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

That all changed on July 16, 2026.

The U.S. Food and Drug Administration approved **Lipfendra (enlicitide)** , the first-ever oral PCSK9 inhibitor, for adults with high cholesterol. It's a once-daily pill that can slash LDL cholesterol by up to 60%—far beyond what statins can achieve. And it's a fraction of the cost of existing injectable alternatives.

For the first time, patients can get injectable-level cholesterol reduction from a pill they can take at home.

---

## The Numbers That Matter: A 60% Plunge in "Bad" Cholesterol

To understand why this approval is such a big deal, you have to understand the numbers.

About **one in four adults in the U.S.** have high LDL cholesterol, according to the American Heart Association. For years, the standard of care has been statins—drugs that block an enzyme the liver uses to make cholesterol. Statins work, but they have limits. Even at the highest doses, many people need additional help lowering their LDL enough to meet medical guidelines.

Lipfendra can take them the rest of the way.

In two Phase 3 clinical trials involving **3,207 adults** with severe hypercholesterolemia—including those with an inherited condition called heterozygous familial hypercholesterolemia (HeFH)—the results were striking.

| Trial Population | Baseline LDL | LDL Reduction vs. Placebo |

|------------------|--------------|---------------------------|

| **High-risk/ASCVD patients** | 96 mg/dL | **-56%** |

| **HeFH patients** | 119 mg/dL | **-59%** |

In plain English: **Lipfendra reduced "bad" cholesterol by 56% to 59% compared to placebo.**  In a post-hoc analysis, the reduction reached **60%** in some patients.

The drug also lowered other dangerous lipids, including non-HDL cholesterol by up to 54% and apolipoprotein B by up to 50%.

**The bottom line:** Lipfendra can take patients to cholesterol levels that were previously only achievable with expensive, inconvenient injectable drugs—or not achievable at all.

---

## How It Works: The PCSK9 Pathway

To understand why Lipfendra is such a breakthrough, you need to understand the biology.

Your liver produces a protein called **PCSK9** that essentially destroys the LDL receptors on the surface of your liver cells. Those receptors are responsible for clearing "bad" cholesterol from your blood. The more PCSK9 you have, the fewer receptors you have, and the more cholesterol stays in your bloodstream.

Lipfendra is a **macrocyclic peptide**—a molecule designed to bind to circulating PCSK9 and block its interaction with the LDL receptor. By blocking PCSK9, it prevents the destruction of LDL receptors, allowing more receptors to remain on the surface of liver cells to clear LDL-C from the blood.

In other words: **Lipfendra unblocks your body's natural cholesterol-clearing machinery.**

This is the same mechanism used by injectable PCSK9 inhibitors that have been available for more than a decade. But those drugs require injections and have list prices that can exceed $500 to $600 per month. Lipfendra is a pill you take once a day—and it costs **$315 for a 30-day supply.** 

---

## The Price Point: A Game-Changer for Access

One of the biggest barriers to PCSK9 inhibitors has been cost. Injectable PCSK9 drugs like Repatha and Praluent have list prices that can exceed $500 to $600 per month, and while insurance coverage has improved, many patients still face high copays or prior authorization hurdles.

Lipfendra's list price is **$315 per month**—roughly half that of the injectable alternatives.

**The drug will be available in a matter of weeks,** according to Merck.

The lower price point could dramatically expand access. As RBC Capital Markets analyst Trung Huynh noted, "an estimated 70% (and more) of eligible high-risk atherosclerotic cardiovascular disease patients remain undertreated; driven by injection aversion, prior authorization burden, and limited specialist access in primary care."

For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable. For patients who couldn't afford the injectables, Lipfendra could be the first time they can access this level of cholesterol reduction.

---

## The Human Element: What This Means for Patients

### For the Patient Who Can't Tolerate Statins

Up to 10% of patients experience muscle pain or other side effects from statins. For them, the options have been limited. Lipfendra offers a completely different mechanism—and it can be used in patients who are already taking statins, or potentially as an alternative for those who can't tolerate them.

### For the Patient with Familial Hypercholesterolemia

HeFH is an inherited condition that causes extremely high cholesterol levels from birth. Patients with HeFH often have LDL levels above 190 mg/dL and are at dramatically increased risk of early heart attacks. In the HeFH trial, patients had an average baseline LDL of 119 mg/dL—even while already taking maximally tolerated statin therapy. Lipfendra lowered their LDL by 59%.

### For the Patient at High Risk

For patients who have already had a heart attack or stroke—or who are at high risk for one—the new AHA/ACC guidelines recommend LDL targets below 70 mg/dL. In the high-risk trial, patients taking Lipfendra saw their LDL drop from 96 mg/dL to well below that threshold.

### For the Patient Who Hates Needles

This one is simple. Some patients simply don't want shots. Lipfendra eliminates that barrier entirely.

As Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston, told The New York Times: **"I'm thrilled."** 

---

## The Catch: Fasting Requirements and Side Effects

No drug is perfect, and Lipfendra has its limitations.

**The fasting requirement is strict.** The pill must be taken on an empty stomach. Patients must take the tablet in the morning and avoid food for a period after dosing.

**The side effects are mild.** In the high-risk trial, the frequency of adverse reactions was similar between those treated with Lipfendra and those receiving placebo. In the HeFH trial, the most common side effects occurring at higher frequencies than placebo were **diarrhea and dizziness.** 

**The big unknown:** While the trials showed that Lipfendra provides significant reductions in atherogenic lipoproteins, **it is not yet known if the treatment can reduce the risk of cardiovascular morbidity and mortality.**  Merck is conducting ongoing trials to determine whether the drug can actually prevent heart attacks and strokes. This is a critical distinction: lowering cholesterol is a surrogate endpoint; preventing cardiovascular events is the real goal.

---

## The Bigger Picture: What This Means for Merck

For Merck, Lipfendra is more than just a new drug—it's a **strategic lifeline.**

The company's blockbuster cancer treatment Keytruda is set to lose key patent protections starting in 2028, exposing the company to competition from biosimilar versions. Keytruda has been one of the world's top-selling medications for years. The company desperately needs new revenue streams to fill the gap.

Lipfendra could be that revenue stream. Analysts project peak sales of **$3.5 billion to $5 billion** by the early 2030s. Some have suggested "tens of billions of dollars" in potential. Merck shares rose 4% on the approval news.

The drug also received a **Priority Review** designation and was part of the FDA Commissioner's National Priority Voucher program, which is intended to slash review periods for drugs that are critical to public health or national security.

**Lipfendra is Merck's best hope for replacing Keytruda's revenue.** And with a pill that's cheaper, more convenient, and just as effective as injectable alternatives, it has the potential to reshape the entire cholesterol management market.

---

## What This Means for the Cholesterol Drug Market

### The Injectable PCSK9 Market Is in Trouble

Injectable PCSK9 inhibitors have been on the market for more than a decade, but they've never achieved the blockbuster sales that analysts once predicted. The reasons are clear: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

Lipfendra addresses all three problems. It's cheaper (roughly half the price), it's a pill (no needles), and it's more convenient. **For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable.**

### The Statin Market Is Under Pressure

Statins have been the standard of care for cholesterol management for decades. They're cheap, generic, and effective. But they can only lower LDL by about 30-50% at maximum doses. For patients who need to get below 70 mg/dL, statins alone often aren't enough.

Lipfendra is a **complement**, not a replacement, for statins. It's approved for use in patients who are **already taking maximally tolerated statin therapy.**  But it could also be used as an alternative for patients who can't tolerate statins—and that could put pressure on the statin market over time.

### The Oral PCSK9 Era Has Arrived

Lipfendra is the first oral PCSK9 inhibitor, but it won't be the last. AstraZeneca is developing its own oral PCSK9 candidate, laroprovstat, which is still in Phase III trials. Merck's approval validates the entire class. **Within five years, the PCSK9 market could shift from injectables to pills.**

---

## Frequently Asked Questions

### Q: What is Lipfendra?

Lipfendra (enlicitide) is the first oral PCSK9 inhibitor approved by the FDA. It's a once-daily pill that lowers "bad" LDL cholesterol by up to 60%.

### Q: How does it work?

Lipfendra blocks the PCSK9 protein, which normally destroys LDL receptors on liver cells. By blocking PCSK9, it allows more LDL receptors to remain on the surface of liver cells to clear cholesterol from the blood.

### Q: How much does it cost?

Lipfendra has a list price of **$315 for a 30-day supply**—roughly half the cost of injectable PCSK9 inhibitors.

### Q: Who is it for?

Lipfendra is approved for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), who are already taking maximally tolerated statin therapy.

### Q: How effective is it?

In clinical trials, Lipfendra lowered LDL cholesterol by **56% to 59%** compared to placebo.

### Q: Does it have side effects?

The most common side effects are **diarrhea and dizziness**. Adverse event rates were similar between Lipfendra and placebo in the main trial.

### Q: Does it require fasting?

Yes. Patients must take it on an empty stomach.

### Q: Can it prevent heart attacks?

We don't know yet. While the drug lowers cholesterol, Merck is conducting ongoing trials to determine if it can reduce the risk of cardiovascular morbidity and mortality.

### Q: Is it better than statins?

It's different. Lipfendra works through a completely different mechanism than statins. It's not a replacement for statins—it's approved for use in patients already taking statins. But it can lower cholesterol far below what statins can achieve alone.

### Q: When will it be available?

Merck says the drug will be available in **a matter of weeks.** 

---

## Conclusion: A New Era in Cholesterol Management

The FDA approval of Lipfendra is a watershed moment in cardiovascular medicine. For the first time, patients have access to a once-daily pill that can lower "bad" cholesterol by up to 60%—matching the power of expensive injectable drugs at half the cost.

**This is not just a new drug. It's a new paradigm.**

Statins have been the backbone of cholesterol management for decades. They're effective, but they have limits. For millions of patients who can't reach their LDL targets—or who can't tolerate statins at all—Lipfendra offers a completely new path forward.

The drug works through a different mechanism than statins. It's a pill, not an injection. It's half the price of injectable alternatives. And it will be available in a matter of weeks.

Of course, there are caveats. The fasting requirements are strict. We don't yet know if the drug can actually prevent heart attacks and strokes. And the drug's effectiveness in "real-world" patients—outside the controlled environment of clinical trials—remains to be seen.

But for patients who have been waiting for a better option—who have struggled with statin side effects, who couldn't afford injectable PCSK9 inhibitors, or who simply couldn't get their cholesterol low enough—Lipfendra is a game-changer.

As one patient advocacy group put it: **"We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering."** 

The era of the injectable PCSK9 inhibitor may be ending. The era of the oral PCSK9 inhibitor has just begun. And for millions of Americans at risk of heart disease, that's a development worth celebrating.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. Lipfendra (enlicitide) is a prescription medication that should only be taken under the supervision of a qualified healthcare provider. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Drug pricing, availability, and clinical trial data are subject to change. You should consult with your doctor or other qualified healthcare professional before starting, stopping, or changing any medication.

---

*Published: July 18, 2026*

---Read more

**Tags:** Lipfendra, enlicitide, PCSK9 inhibitor, cholesterol medication, FDA approval, LDL cholesterol, Merck, heart disease, statins, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease, cholesterol pill, oral PCSK9, Repatha, Praluent, Keytruda, cholesterol management, heart attack prevention